CinCor Pharma Net Income

The latest net income for CINC is $-93M as of September 2022. That compares with $-27M in the prior-year period — down 247.7% year over year. That is below the sector sector average of $90M. Investors often review this figure alongside CinCor Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CINC's net income moved from $-27M to $-93M — a 247.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CinCor Pharma's operating scale or balance-sheet position.

Against its sector companies, CINC currently prints $-93M for net income, while the sector average sits near $90M. That is roughly 203.4% below the sector mean. Large gaps often invite a closer look at CinCor Pharma's growth, margins, and balance sheet.

A net income figure of $-93M for CINC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $90M. Explore the charts below for those layers of context.

After noting CINC's net income ($-93M), review year-over-year change from $-27M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.